{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001125345","name":"MACROGENICS INC","summary":"MacroGenics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for cancer treatment. It generates product candidates from proprietary platforms including DART and TRIDENT bispecific antibodies and antibody-drug conjugates (ADCs). Key pipeline assets include lorigerlimab, MGC026, and MGC028. The company also operates a commercial-scale cGMP antibody manufacturing facility and provides contract development and manufacturing services. Three partnered products—ZYNYZ, MARGENZA, and TZIELD—have received FDA approval.","people":[],"products":[{"name":"MGC026","type":"platform","description":"Investigational ADC targeting B7-H3 with a novel TOP1i-based linker-payload SYNtecan E, in Phase 1 dose escalation and expansion studies."},{"name":"MGC028","type":"platform","description":"First-in-class investigational ADC targeting ADAM9 with a novel TOP1i-based linker-payload, in Phase 1 dose escalation in advanced solid tumors."},{"name":"MGC030","type":"platform","description":"Preclinical first-in-class ADC targeting an undisclosed antigen expressed across several solid tumors; IND submission targeted Q3 2026."},{"name":"Lorigerlimab","type":"platform","description":"Investigational bispecific tetravalent DART molecule targeting PD-1 and CTLA-4; in LINNET study for platinum-resistant ovarian cancer under partial FDA clinical hold."},{"name":"MGD024","type":"platform","description":"Investigational bispecific CD123xCD3 DART molecule for hematologic malignancies including AML and MDS; in Phase 1 under Gilead collaboration."},{"name":"ZYNYZ (retifanlimab-dlwr)","type":"platform","description":"FDA-approved anti-PD-1 monoclonal antibody out-licensed by MacroGenics."},{"name":"MARGENZA (margetuximab-cmkb)","type":"platform","description":"FDA-approved anti-HER2 monoclonal antibody sold to a partner; MacroGenics retains certain economic rights."},{"name":"TZIELD (teplizumab-mzwv)","type":"platform","description":"FDA-approved anti-CD3 mAb for delaying onset of Stage 3 type 1 diabetes; sold to Provention Bio, later acquired by Sanofi."}],"partnerships":[{"partner_name":"Gilead Sciences, Inc.","partnership_type":"development","description":"Exclusive option and collaboration agreement to develop and commercialize MGD024 and up to two additional bispecific research programs using DART/TRIDENT platforms.","start_date":null},{"partner_name":"Synaffix B.V. (a Lonza company)","partnership_type":"licensing","description":"Collaboration partner providing GlycoConnect technology used in site-specific conjugation for MGC026 ADC.","start_date":null},{"partner_name":"Sanofi","partnership_type":"licensing","description":"Acquired Provention Bio which had purchased teplizumab (TZIELD) from MacroGenics; MacroGenics retains milestone and royalty rights.","start_date":null},{"partner_name":"DRI Healthcare Trust","partnership_type":"licensing","description":"MacroGenics sold its royalty interest in TZIELD to a wholly-owned subsidiary of DRI Healthcare Trust for $100.0 million in March 2023.","start_date":null}],"affiliations":[],"origin":{"leaf":"2f3ba30331e6c54e32e1d1e56a1d35b002b5e5257f1a5071b747442de440ea95","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"8671a24c375faeda927b3c90b7799907b5180ecf574f7c60541aa58899bd505a","parent":"8bc3ebd13475f212e4a6b0d2d7315ae3e41c6f9c27c43d4ac3eaf0815a38d786","source":"0001125345-26-000017","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":500,"hourly_limit":500,"remaining":0,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}